Benzinga
Benzinga
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Benzinga
mardi, octobre 20
Actualités France
Bourse
Economie
Général
Actualités Américaines
Bourse
Bénéfices
Economie
Marchés prédictifs
Marchés privés
Autres marchés
Recommandations des analystes
Trading
Communiqués de presse
Mondial
Asie
Crypto-monnaies
Actualités cryptos
Altcoins
Bitcoin
Dogecoin
Ethereum
Shiba Inu
NFT
Éducation
Investir en crypto
Investir en bourse
Forex
Agios Pharmaceuticals Inc
AGIO
NASDAQ
Liste de surveillance
Get Report
Trade with Public
Get Report
Trade with Public
$36.72
1.82
5.2%
Dern. MÀJ: Oct 20, 2:43 PM
$35.00
0.10
0.29%
Get Report
Aperçu
Actualités
Prévisions de résultats
Événements
Objectifs de cours
Données financières
Sentiment
Actionnariat
Comparer
Options
Rapport sur les stocks
Privacy Manager
Agios Pharmaceuticals Financials
Agios Pharmaceuticals (AGIO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Agios Pharmaceuticals Q2 EPS $(1.69) Misses $(1.67) Estimate, Sales $44.745M Beat $25.521M Estimate
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.69) per share which missed the analyst consensus estimate of $(1.67) by 1.2 percent. This is a 12.44 percent increase over losses of $(1.93) per share
Benzinga Newsdesk
Earnings Scheduled For April 29, 2026
Benzinga Insights
PRO
Agios Pharmaceuticals Q1 EPS $(1.69) Beats $(1.79) Estimate, Sales $20.746M Beat $13.646M Estimate
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.69) per share which beat the analyst consensus estimate of $(1.79) by 5.59 percent. This is a 9.03 percent decrease over losses of $(1.55) per share
Benzinga Newsdesk
Earnings Summary: Agios Pharmaceuticals Q4
Benzinga Insights
PRO
Agios Pharmaceuticals Q4 EPS $(1.86) Beats $(1.94) Estimate, Sales $19.967M Beat $12.014M Estimate
Agios Pharmaceuticals (NASDAQ:AGIO) reported quarterly losses of $(1.86) per share which beat the analyst consensus estimate of $(1.94) by 3.93 percent. This is a 4.12 percent increase over losses of $(1.94) per share
Benzinga Newsdesk
Earnings Scheduled For February 12, 2026
Benzinga Insights
